Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 févr. 2022 07h00 HE | Source: CareDx, Inc.

CareDx Joins Forces with MOTTEP, The National Minority Organ Tissue Transplant Education Program, to Host “Heart Health” Webinar for Transplant Patients

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
03 févr. 2022 07h00 HE | Source: CareDx, Inc.

CareDx To Participate In Upcoming Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
20 janv. 2022 07h00 HE | Source: CareDx, Inc.

CareDx Joins Forces with MOTTEP to Increase Organ Donations for Minority Transplant Patients and Support High-Risk, Underserved Communities

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
12 janv. 2022 07h00 HE | Source: CareDx, Inc.

Landmark ADMIRAL Study Publication with CareDx’s AlloSure Kidney is the First Long-Term Multicenter Prospective Clinical Validation for Routine Organ Transplant Surveillance

ADMIRAL Study Shows AlloSure Detects Clinical and Subclinical ABMR and TCMR, and Predicts Long-Term Outcomes for Kidney Transplant Patients AlloSure Showed 62% Improvement Over Standard of Care Serum...
11 janv. 2022 07h00 HE | Source: CareDx, Inc.

CareDx Partners with Multiple Biotechnology Companies to Use AlloCell in CAR T-Cell Therapy Clinical Studies

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
10 janv. 2022 07h00 HE | Source: CareDx, Inc.

CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) -- The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
07 janv. 2022 07h00 HE | Source: CareDx, Inc.

NIH Study Shows Using CareDx’s AlloSure Lung for Transplant Surveillance is More Effective than Diagnostic Bronchoscopy at Identifying Rejection

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
06 janv. 2022 07h00 HE | Source: CareDx, Inc.

CareDx Successfully Completes CLIA Validation of AlloMap Kidney in Preparation for Commercial Launch

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
05 janv. 2022 07h00 HE | Source: CareDx, Inc.

CareDx Expands Its Medication Adherence Services with the Acquisition of The Transplant Pharmacy

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
04 janv. 2022 07h00 HE | Source: CareDx, Inc.

CareDx Partners with ISHLT in a Transplant Innovation Research Grant to Improve Outcomes for Heart and Lung Transplant Patients

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...

Page précédente

Page suivante